A Phase 3 interventional study of Blood sampling and Lidocaine in Obesity and Bariatric Surgery, sponsored by Hospices Civils de Lyon. Completed at 1 site in France. Open to participants aged 18 Years to 68 Years. Per ClinicalTrials.gov, last updated 2025-12-19.
Sponsored by Hospices Civils de Lyon · Phase 3, Interventional, and Basic science
Intravenous lidocaine is efficient for management of post operative pain in abdominal surgery. As previously published in literature the investigators use it during bariatric surgery.
Nevertheless plasmatic concentration of lidocaine is unknown in this population, despite a widespread use.
Investigators propose in this work to bring an objective proof that administration of lidocaine based on a modified body weight is safe.
Intravenous administration concerned the peri operative period. A total of six samples are taken for each patient.
Investigators get approbation of local ethic committee for this work.
6,296 studies on the registry are indexed under Obesity; 1,695 are open to participants now.
This study's enrollment of 50 is below the median of 78 across 4,878 interventional studies indexed under Obesity.
Browse Obesity studies →Hospices Civils de Lyon is the lead sponsor of 1,826 studies on the registry; 439 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients will receive intravenous administration of lidocaine based on a modified body weight ; blood sampling will be performed to assess plasmatic concentration of lidocaine
Biological: Blood sampling · Drug: Lidocaine
Plasmatic concentration of lidocaine
Blood samples will be removed by the peripheral catheter or direct venous puncture with other blood sample usually performed during post-operative period. First sample will be taken after initial bolus (ie 10 min after initiation of perfusion), second at 20 min, third at 30 min. The fourth and fifth samples will be taken after change of posology (from 2 to 1 mg/kg/h at the end of surgery) and at the end of administration. The sixth sample will be performed the day after the end of administration.
Time frame: From bolus to day 1 after cessation of administration
occurence of adverse events related to lidocaine use
neurologic (seizure, dysgeusia, dizziness) or cardiologic events (atrio ventricular block, ventricular rhythm disorder) will be assessed after surgery, during hospitalization in post-operative room or intensive care unit.
Time frame: Up to 2 days after surgery
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospices Civils de Lyon